ERBB2 and neoplasm: T cells with a chimeric receptor displaying the extracellular domain of HER2 and the intracellular domain of CD96 showed decreased killing activity against HER2-positive tumor cells compared to T cells lacking the intracellular CD96 domain in vitro and in vivo [34].